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adjustment for age, gender, ethnicity, and surgical treatment. Among 
stage IV NSCLC cases, those with ipsilateral intrapulmonary metasta-
sis (n=1120) had improved OS (13m) compared to those with bilateral 
intrapulmonary metastasis (n=1890; OS=7m) (P < 0.0001) (Figure 2).
Conclusions: Among stage IIIB and IV NSCLC cases, those present-
ing with ipsilateral intrapulmonary metastasis have improved survival 
outcomes. Our results add further support for modiﬁcation to the cur-
rent non-small-cell lung cancer staging system.
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Purpose: To evaluate the usefulness of FDG-PET/CT (PET/CT), supe-
rior to CT, for determining tumor response to treatment after stereotac-
tic radiosurgery (SRS) in primary or metastatic lung cancer
Methods: Thirty-ﬁve patients, with lung tumor, treated with SRS 
between July 2004 and June 2006 were reviewed. Treatment aim was 
curative or salvage in 30 primary or recurrent lung cancer patients, 
palliative in 15 metastatic lung cancer patients. SRS delivered 36, 48, 
or 60 Gy radiation, 12 or 20 Gy per fraction, to gross tumor with 5mm 
margin for 3 or 4 days consecutively. PET/CT was checked twice for 
measuring changes of maximal standardized uptake value (SUVmax), 
1 or 2 months before and after SRS, and CT was checked coincidently. 
Evaluation of tumor response with PET/CT used a level of SUV 
change, and response criteria were divided into complete remission 
(CR; maximal SUV decrease ≥70%), partial remission (PR; 10-69% 
decrease), no response (NR; 10% decrease-10% increase), and disease 
progression (PD; >10% increase)
Results: SUVmax value in PET/CT before and after SRS were 
0.80-13.10 (median 5.3) and background uptake-7.20 (median 1.70) 
respectively. Decrease rate of SUVmax was (-25.0)-98.3% (median 
50.0%). Metabolic response judged by PET/CT was CR in 17 (37.8%), 
PR in 19 (42.2%), NR in 8 (17.8%), and PD in 1 (2.2%) patients. Clini-
cal response judged by CT was CR in 2 (4.4%), PR in 18 (45.0%), NR 
in 20 (44.5%), PD in 5 (11.1%) patients. Peritumoral radiation induced 
pneumonitis or ﬁbrosis was a confounding factor for evaluation with 
CT especially in PD or NR groups, but PET/CT could differentiate such 
inﬂammatory lesion with actual tumor progression in some patients.
Conclusion: PET/CT at 1 month after SRS could reﬂect actual re-
sponse better than CT examined coincidently. FDG-PET/CT at 1 month 
before and after SRS might be a useful modality for evaluation of 
tumor response after treatment
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Background: We showed that PCG signiﬁcantly increases both 
Response Rate (RR) (43.6% vs 20%) and median survival time (10.8 
mo vs 8.3 mo) over PC and that at Cox analysis, the only independent 
prognostic factors were PS and Treatment (Paccagnella et al, J Clin 
Oncol 2006;24: 681-687).
According to the Prentice criteria (Stat Med 1989;8: 431-440), to 
directly relate Response and Survival it is necessarily that Responding 
patients (and non Responding) for both arms have a similar survival 
and that the survival difference between the two arms disappear when 
the Response Factor is included in the Multivariate Analysis.
Methods: Out of 324 pts included in the original analysis, 26 pts not 
evaluable for response (early death, toxicity, refusal) before the planned 
response evaluation at two months were excluded (15 pts from PC arm 
and 11 pts from PCG arm). The analysis was however also performed 
considering the no evaluable patients as non responders.
Results: Overall, Responder patients had a median Survival that nearly 
doubled that of no Responders: 14.73 mo vs 7.67 mo (HR: 0.49; CI: 
0.31 - 0.54; P= 0.000). 
No Responders pts from PC and PCG arms had a similar survival (me-
dian 7.53 mo and 8.07 mo respectively; P= 0.96) as well as respond-
ers (CR + PR) patients (median 14.13 mo and 15.40 mo respectively; 
P=0.38).
The only difference between the two arms was that more than the 
double of patients in PCG arm responded (43.6% vs 20%) and conse-
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quently had a survival advantage of clinical relevance. When tumor 
response was introduced in the Cox model (as a four level variable), the 
difference in Overall Survival between PCG and PC changed from a 
signiﬁcant level (HR=1.28; CI 1.00-1.63; P=0.049) to a not signiﬁcant 
level (HR=0.99; CI: 0.76 - 1.28; P=0.97). 
Conclusions: To our knowledge this is the ﬁrst report showing a sig-
niﬁcant direct correlation between Response and Survival in NSCLC 
according to Prentice criteria.
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Background: ACTION (Assessment of Costs and ouTcomes of 
chemotherapy In an Observational setting in patients with advanced 
NSCLC) is a prospective, pan-European observational study. The ob-
jective of ACTION is to describe advanced NSCLC treatment patterns 
and patient outcomes in routine clinical practice.
Methods: Chemonaive patients (pts) aged ≥ 18 yrs with stage IIIb/IV 
NSCLC were observed for 18 months from presentation for initiation 
of ﬁrst line chemotherapy (CT). All pt care, including CT given, was at 
the discretion of the pt/physician. Pts were excluded if participating in 
a clinical trial. Overall survival was estimated using the Kaplan Meier 
method. Assessment of prognostic factors for survival was performed 
using Cox’s proportional hazards model.
Results: 975 patients were enrolled between April 2003 and Septem-
ber 2004, with observations completed in March 2006. Median age 
was 65 yrs (32-90) with 28.3% of pts aged ≥70 yrs; 71.3% were male; 
65.2% had stage IV disease. Of 487 pts who experienced weight loss, 
172 lost >10% body weight in 4 weeks prior to the start of CT. Overall 
WHO PS at baseline was 0 (21.1%), 1 (65.1%), 2 (10.0%), 3 (3.3%), 4 
(0.5%). One-year survival rate was estimated to be 39.5%. Unadjusted 
median survival time for all pts was 9.3 months (mo) (95% CI 8.6-
10.3), for pts receiving 3rd generation CT [either gemcitabine (gem), 
vinorelbine (vino) or taxane] with a platinum compound as ﬁrst line 
CT: 9.9 mo (8.6 - 10.7), for pts receiving ﬁrst line monotherapy (either 
gem or vino): 9.7 mo (7.3-12.3) and for pts receiving any other CT: 7.9 
mo (6.4-9.3). Assessment of prognostic factors for survival resulted in 
a ﬁnal Cox proportional Hazard model including treatment, WHO PS, 
number of metastatic organs, gender and age as prognostic factors. The 
hazard ratio (HR) for pts with baseline WHO PS 1 vs. PS 0 was 1.224 
(95% HR Conﬁdence Limits 0.994 - 1.509), baseline WHO PS 2 vs. 
PS 0: HR 2.006 (1.466 - 2.745), baseline WHO PS 3/4 vs. PS 0: 2.790 
(1.799 - 4.328). The HR for pts with 1 metastatic organ at baseline vs. 
none was 0.947 (0.777 - 1.154), 2 vs. 0: 1.111 (0.866 - 1.424), 3 vs. 0: 
1.301 (0.870 - 1.944) and 4-6 vs. 0: 3.442 (2.082 - 5.592). For female 
vs. male pts the HR was 0.716 (0.592 - 0.866). The HR for baseline age 
was 0.991 (0.982 - 1.000).
Conclusion: ACTION is the ﬁrst large-scale observational study of 
pts with advanced NSCLC. Median survival is comparable to previ-
ous clinical trial results (e.g. le Chevalier et al, 2005); even though 
the prognosis for these pts indicated that a worse outcome was likely. 
Analysis of factors inﬂuencing survival also reinforce previous clinical 
trial results, as it is seen that gender, baseline WHO PS and disease 
stage signiﬁcantly impact on overall survival, as reported in Schiller et 
al (2002).
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Background: Pemetrexed exhibited comparable efﬁcacy and mild 
toxicity in a phase III trial comparing pemetrexed 500 mg/m2 with 
docetaxel 75 mg/m2 in vitamin-supplemented advanced NSCLC 
patients. A second phase III trial was initiated to determine if the peme-
trexed dose could be escalated to increase efﬁcacy, without resulting in 
an unacceptable increase in toxicity.
Methods: Patients with locally advanced or metastatic NSCLC, previ-
ously treated with platinum-based chemotherapy, were randomized to 
iv pemetrexed 500 (P500) or pemetrexed 900 mg/m2 (P900) q 3week. 
The study was terminated after 588 out of 600 patients had enrolled 
since an interim analysis indicated a low probability of a survival ad-
vantage and somewhat greater frequency of toxicity on the P900 arm. 
Patients were allowed to continue treatment at the P500 dose.
Results: Baseline characteristics of patients were balanced on both 
arms: ~67% males, median age 62 yrs, 87% pts with an ECOG PS of 
0 or 1, and 77% pts with stage IV disease. Five hundred eighty-eight 
randomized patients were evaluated for survival; 581 patients, who 
received ≥1 dose, for safety; 509 patients, who received ≥2 cycles and 
had measurable disease, for tumor response. Safety data for patients 
who switched from P900 to P500 were analyzed separately. There was 
no statistical difference between treatment arms for any efﬁcacy mea-
sure: median survival P500 6.7 mo versus P900 6.9 mo, HR=1.0132 
(95% CI 0.837, 1.226); progression-free survival P500 2.6 mo versus 
P900 2.8 mo, HR=0.9681 (95% CI 0.817, 1.147); best overall tumor 
response (all PR) P500 7.1% versus P900 4.3% (p=0.1616). As sum-
marized in the table below, the frequency of Grade 3/4 CTC toxicity 
was somewhat higher in the P900 arm. Likewise, patients on the P900 
arm were hospitalized more frequently for drug-related adverse events 
(P500: 10.7% patients; P900 arm: 15.8% patients), and required more 
blood transfusions (% patients requiring **1 transfusion: P500: 16.9%, 
P900 arm: 20.4%).
